Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Follicular × abexinostat × Lymphoid × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 3 Multiple Myeloma 2 Lymphoma, Large B-Cell, Diffuse 2 Hodgkin Disease 2 Neoplasms by Site 1 Neoplasms 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Bronchiolitis Obliterans Syndrome 1

Interventions

Rituximab 271 Cyclophosphamide 222 fludarabine phosphate 97 Peripheral Blood Stem Cell Transplantation 97 Filgrastim 84 Etoposide 77 Radiotherapy 75 Prednisone 74 Lenalidomide 74 Vincristine 73 Mycophenolic Acid 59 Doxorubicin 59 Bendamustine Hydrochloride 55 Whole-Body Irradiation 54 Cyclosporine 53 fludarabine 48 Melphalan 48 obinutuzumab 46 Tacrolimus 44 Cytarabine 43 Busulfan 42 Methotrexate 39 Antilymphocyte Serum 36 Bortezomib 33 Methylprednisolone 32 Carmustine 31 sargramostim 30 ibritumomab tiuxetan 29 ibrutinib 28 Dexamethasone 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03600441 2025-04-10

FORERUNNER

Xynomic Pharmaceuticals, Inc.

Phase 2 Active not recruiting

Lymphoma, Follicular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡